Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, double-blind, randomized, placebo-controlled, sequential-group study of single ascending doses of KPL-716 in healthy volunteers and subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus following intravenous or subcutaneous administration

Trial Profile

A Phase Ia/Ib, double-blind, randomized, placebo-controlled, sequential-group study of single ascending doses of KPL-716 in healthy volunteers and subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus following intravenous or subcutaneous administration

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs KPL-716 (Primary)
  • Indications Atopic dermatitis; Pruritus
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 01 Nov 2018 According to a Kiniksa Pharmaceuticals media release, repeated-single-dose Phase 1b results expected in 2H 2019.
    • 15 Sep 2018 According to a Kiniksa Pharmaceuticals media release, data presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
    • 15 Sep 2018 Results published in the Kiniksa Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top